Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.32 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2247852 | 0.71 | ALDH1A1 (0.39) | KDM4EALDH1A1GAAEGFR | |
| SCHEMBL5958154 | 0.71 | EGFR (0.33) | EGFR | |
| SCHEMBL30858956 | 0.71 | EGFR (0.37) | ALDH1A1GAAL3MBTL1EGFR | |
| SCHEMBL3235816 | 0.71 | EGFR (0.33) | EGFR | |
| SCHEMBL17926571 | 0.71 | EGFR (0.33) | EGFR | |
| SCHEMBL9072335 | 0.71 | EGFR (0.37) | ALDH1A1GAAL3MBTL1EGFR | |
| SCHEMBL19957964 | 0.70 | EGFR (0.39) | KDM4EALDH1A1LMNAEGFR | |
| Hydrochloric Acid SCHEMBL31194800 | 0.69 | EGFR (0.36) | ALDH1A1GAAL3MBTL1EGFR | |
| Hydrochloric Acid SCHEMBL31194830 | 0.69 | EGFR (0.38) | LMNAEGFR | |
| SCHEMBL1924456 | 0.67 | EIF4E (0.38) | RPS6KA5RPS6KA4KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| EP-2611809-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030924-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, JAK1 | PSMB8 4377/4885KDR 933/4885RPS6KA5 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.